The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price has jumped into the green during afternoon trade on Friday.
Neuroscientific shares are on the move as the company released an announcement on its EmtinB label.
Let's investigate further.
What did Neuroscientific announce?
After recommencing trade after Thursday's trading pause, Neuroscientific provided additional colour on its announcement from 19 August.
Recall that Neuro' announced on Thursday that its EmtinB label indicated "strong therapeutic potential" in "preventing severe immune responses from Covid-19".
It achieved this by reducing "important biomarkers" associated with "severe Covid-19…by more than 50%".
As such, Neuro' advised the "serves as clarification" on these results. Consequently, the aim was to provide further clarity "regarding the specifics of the studies".
The explicit clarification as it were, is in reference to EmtinB's mechanism of action in the trials.
To illustrate, on Thursday the company gave a high-level overview of this, whereas, on Friday, Neuro' went into greater depths over just how EmtinB "does what it says on the tin" in this instance.
For instance, the company explained that EmtinB can "dramatically reduce" these biomarkers, which have been identified in "Covid-19 clinical studies as indicators of severe disease and poor prognosis".
Consequently, Neuroscientific reasons that by decreasing these "immune biomarkers", this indicates that EmtinB "may decrease" an inflammatory response that is significantly elevated due to Covid-19.
What did management say?
Speaking on the announcement, Neuroscientific managing director Matt Liddelow said:
These results demonstrate the significant therapeutic utility of EmtinBTM and its potential modulation of
inflammatory processes outside of the central nervous system. For the first time, our team
have demonstrated an EmtinBTM -mediated effect on adaptive immune responses as
evidenced by regulation of these inflammatory biomarkers.
Neuroscientific share price snapshot
The Neuroscientific Biopharmaceuticals share price has posted a year to date return of 34%, extending the previous 12 month's gain of 42.5%.
These results have outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of around 25% over the past year.
